Chase Bank Chief Economist Anthony Chan says even though corrections occur investors should focus on improving fundamentals.
Eli Lilly CEO John Lechleiter gives his outlook for growth and new products.
Eli Lilly CEO John Lechleiter argues the company doesn’t need to make bid deals to grow.
Rehmann Financial Principal Joe Heider on the health-care stocks to watch.
Alkeus Pharmaceuticals CEO Leonide Saad on the company’s research.
Citigroup Institutional Clients Group vice Chairman Leon Kalvaria gives his outlook for the M&A market.
Medical device maker Zimmer Holdings Inc said it would buy orthopedic products company Biomet Inc in a deal valued at about $13.35 billion to broaden its portfolio o...
U.S. drugmaker Eli Lilly and Co reported lower-than-expected quarterly revenue on Thursday, hurt by disappointing sales of its cancer and diabetes drugs.Lilly said i...
High-priced pharmacy deals are all the rage this year as big drug companies stung by patent expirations attempt to offset losses and reduce risk and costs by joining...
Amgen (NASDAQ:AMGN) said Tuesday its first-quarter profit dropped 25% amid lower-than-expected sales for the biopharmaceutical firm.The company reported net income o...
Novartis CEO Joe Jimenez on his company’s corporate transformation and focus on pharmaceuticals, eyecare and generics.
FBN’s Maria Bartiromo on U.S. futures and the $25 billion in Novartis deals.
Novartis (NYSE:NVS) is revamping its portfolio with a flurry of deals worth about $25 billion, as the Swiss pharmaceutical giant plans to swap assets with GlaxoSmith...
Eli Lilly CEO John Lechleiter discusses his outlook for growth and when he expects to have patent expirations behind.
Earnings HQ: FBN’s Lori Rothman breaks down Eli Lilly ’s third-quarter earnings report.
Eli Lilly CEO John Lechleiter discusses 2Q earnings and the impact of recent patent expirations.
Earnings HQ: FBN’s Ashley Webster breaks down Eli Lilly ’s second-quarter earnings report.
Aratana Therapeutics CEO Steven St. Peter on what’s driving growth in the animal-health business.
Eli Lilly CEO John Lechleiter on where we are in the fight for cancer.
Schulte, Roth & Zabel managing partner Paul Roth weighs in on the U.S. corporate tax rate.